This pattern may reflect inflammation- and hypoxia-driven activation of endothelin-1 and the renin–angiotensin–aldosterone system, leading to significant vasoconstriction, pulmonary hypertension, and eGFR decline with evolving CKD. The gene discussed is REN; the disease is pulmonary arterial hypertension.